SAN FRANCISCO, CALIFORNIA--April 14, 2011--Medizone International, Inc. (OTCBB:MZEI) (OTCQB:MZEI) announced today that its highly-acclaimed, ozone-based decontamination and
infection control technology, AsepticSure™, will be officially launched at one of the world's premier medical expo events - FIME Miami - on August 10-12, 2011 at the Miami Beach Convention Center.
The buzz in medical science circles around AsepticSure's potential contribution to global infection control, both in and out of the hospital and broader healthcare environment, is "contagious" to say the least!
Medizone's CEO, Edwin Marshall, commented, "When you're sitting on clinically proven
hospital beta-tested technology capable of consistently delivering between 6--7.9 log₁₀ kill rates against the likes of MRSA, VRE, E.coli, P. Aeruginosa, C.difficile, and B. subtilis, you get a strong sense that attendees at this year's FIME Show are going to sit up and take note."
And so they should--because as an ozone vapor-based fumigant, AsepticSure's demonstrably rapid, high-level disinfection of surfaces and room spaces 'lends itself' to a lot more than just the hospital and long-term patient care market. Even the interchangeable modular structure of the AsepticSure™ units has been fashioned to accommodate multiple market applications.
Marshall commented regarding the subject of design aesthetics, "By employing advanced modular design concepts, we've been able to develop a production unit that's seamlessly capable of crossing industries. The exact same units designed to greatly reduce hospital acquired infections from within the healthcare industry will be perfectly adaptable to the decontamination of the larger spaces found within food processing plants, athletic facilities and clean room manufacturing facilities."
Each of these examples represents a sizable global industry on its own and should afford Medizone International tremendous commercial opportunity 'going forward'.
In closing, Marshall stated, "We're really looking forward to being at FIME in August--and the timing of our own commercial schedule is perfect: AsepticSure's final product development for production continues on schedule; our patent program continues on schedule; and, based on preliminary interest being shown from various market sectors in the capability of AsepticSure™, the transition to full commercialization later this year is right on target as well."
For press information on Medizone, please contact:
Investor Relations:
Jack Eversull, President
The Eversull Group, Inc.
T: 001-972-571-1624
F: 001-214-469-2361
E:
jack@theeversullgroup.com
Medizone International, Inc. is engaged in final production development of its AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log is obtainable within hospitals, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
For more information on Medizone please visit
www.medizoneint.com
